Single-Dose Pharmacokinetics of NWP06, an Extended-Release Methylphenidate Suspension, in Children and Adolescents with ADHD

References

• . Merikangas KR, He JP, Brody D, Fischer PW, Bourdon K, Koretz DS. Prevalence and treatment of mental disorders among US children in the 2001–2004. NHANES. Pediatrics. 2010; 125(1):75–81
   PubMed Web of Science ®Google Scholar
• . Pastor PN, Reuben CA. Diagnosed attention deficit hyperactivity disorder and learning disability: United States, 2004–2006. Vital Health Stat 10. 2008; 237:1–14
   Google Scholar
• . Castle L, Aubert RE, Verbrugge RR, Khalid M, Epstein RS. Trends in medication treatment for ADHD. J Atten Disord. 2007; 10(4): 335–342
   PubMedGoogle Scholar
• . Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2010; 59(44):1439–1443
   PubMedGoogle Scholar
• . Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007; 46(7):894–921
   PubMed Web of Science ®Google Scholar
• . Danckaerts M, Sonuga-Barke EJ, Banaschewski T, . The quality of life of children with attention deficit/hyperactivity disorder: A systematic review. Eur Child Adolesc Psychiatry. 2010; 19(2):83–105
   PubMed Web of Science ®Google Scholar
• . Greydanus DE, Nazeer A, Patel DR. Psychopharmacology of ADHD in pediatrics: Current advances and issues. Neuropsychiatr Dis Treat. 2009; 5:171–181
   PubMed Web of Science ®Google Scholar
• . Kimko HC, Cross JT, Abernethy DR. Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet. 1999; 37(6):457–470
   PubMed Web of Science ®Google Scholar
• . Modi NB, Lindemulder B, Gupta S. Single- and multiple-dose pharmacokinetics of oral once-a-day osmotic controlled-release OROS (methylphenidate HCL) formulation. J Clin Pharmacol. 2000; 40(4):379–388
   PubMed Web of Science ®Google Scholar
• . Shaywitz SE, Hunt RD, Jatlow P, . Psychopharmacology of attention deficit disorder: Pharmacokinetic, neuroendocrine, and behavioral measures following acute and chronic treatment with methylphenidate. Pediatrics. 1982; 69(6):688–694
   PubMed Web of Science ®Google Scholar
• . Swanson J, Gupta S, Lam A, . Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: Proof-of-concept and proof-of-product studies. Arch Gen Psychiatry. 2003; 60(2):204–211
   PubMed Web of Science ®Google Scholar
• . Lyseng-Williamson KA, Keating GM. Extended-release methylphenidate (Ritalin LA). Drugs. 2002; 62(15):2251–2259
   PubMed Web of Science ®Google Scholar
• . Childress AC, Spencer T, Lopez F, . Efficacy and safety of dexmethylphenidate extended-release capsules administered once daily to children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009; 19(4):351–361
   PubMed Web of Science ®Google Scholar
• . Pentikis HS, Simmons RD, Benedict MF, Hatch SJ. Methylphenidate bioavailability in adults when an extended-release multiparticulate formulation is administered sprinkled on food or as an intact capsule. J Am Acad Child Adolesc Psychiatry. 2002; 41(4):443–449
   PubMed Web of Science ®Google Scholar
• . McGough JJ, Biederman J, Greenhill LL, . Pharmacokinetics of SLI381 (ADDERALL XR), an extended-release formulation of Adderall. J Am Acad Child Adolesc Psychiatry. 2003; 42(6):684–691
   PubMed Web of Science ®Google Scholar
• . Boellner SW, Stark JG, Krishnan S, Zhang Y. Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: A single-dose, randomized, open-label, crossover study. Clin Ther. 2010; 32(2):252–264
   PubMed Web of Science ®Google Scholar
• . Banaschewski T, Coghill D, Santosh P, . Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry. 2006; 115(8):476–495
   Google Scholar
• . Meltzer EO, Welch MJ, Ostrom NK. Pill swallowing ability and training in children 6 to 11 years of age. Clin Pediatr (Phila). 2006; 45(8):725–733
   PubMed Web of Science ®Google Scholar
• . Findling RL, Wigal SB, Bukstein OG, . Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: A multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials. Clin Ther. 2009; 31(8):1844–1855
   PubMed Web of Science ®Google Scholar
• . Schirm E, Tobi H, de Vries TW, Choonara I, De Jong-van den Berg LT. Lack of appropriate formulations of medicines for children in the community. Acta Paediatr. 2003; 92(12):1486–1489
   PubMed Web of Science ®Google Scholar
• . Num AJ. Making medicines that children can take. Arch Dis Child. 2003; 88:369–371
   PubMed Web of Science ®Google Scholar
• . Conroy S. Unlicensed and off-label drug use: Issues and recommendations. Paediatr Drugs. 2002; 4(6):353–359
   PubMedGoogle Scholar
• . Adler LD, Nierenberg AA. Review of medication adherence in children and adults with ADHD. Postgrad Med. 2010; 122(1):184–191
   PubMed Web of Science ®Google Scholar
• . Childress AC, Berry SA. The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension. Postgrad Med. 2010; 122(5):35–41
   PubMed Web of Science ®Google Scholar
• . Patrick KS, Straughn AB, Jarvi EJ, Breese GR, Meyer MC. The absorption of sustained-release methylphenidate formulations compared to an immediate-release formulation. Biopharm Drug Dispos. 1989; 10(2):165–171
   PubMed Web of Science ®Google Scholar
• . Dopheide JA. The role of pharmacotherapy and managed care pharmacy interventions in the treatment of ADHD. Am J Manag Care. 2009; 15( 5 suppl):S141–S150
   Google Scholar
• . Concerta (methylphenidate hydrochloride) tablets [package insert]. Titusville, NJ: McNeil Pediatrics; 2010
   Google Scholar
• . Daytrana (methylphenidate) film, extended release transdermal [package insert]; Wayne, PA: Shire Pharmaceuticals Inc; 2010
   Google Scholar
• . Mennella JA, Beauchamp GK. Optimizing oral medications for children. Clin Ther. 2008; 30(11):2120–2132
   PubMed Web of Science ®Google Scholar
• . Beck MH, Cataldo M, Slifer KJ, Pulbrook V, Guhman JK. Teaching children with attention deficit hyperactivity disorder (ADHD) and autistic disorder (AD) how to swallow pills. Clin Pediatr (Phila). 2005; 44(6):515–526
   PubMed Web of Science ®Google Scholar
• . Bokhari FAS, Heiland F, Levine P, Ray GT. Risk factors for discontinuing drug therapy among children with ADHD. Health Serv Outcomes Res Method. 2008; 8:134–158
   Google Scholar
• . Greenhill LL, Halperin JM, Abikoff H. Stimulant medications. J Am Acad Child Adolesc Psychiatry. 1999; 38(5):503–512
   PubMed Web of Science ®Google Scholar